NMLS.F Stock Overview
Through its subsidiaries, operates as a biotechnology company worldwide.
Snowflake Score | |
---|---|
Valuation | 0/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 1/6 |
Dividends | 0/6 |
Nova Mentis Life Science Corp. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | CA$0.013 |
52 Week High | CA$0.041 |
52 Week Low | CA$0.0069 |
Beta | 0.68 |
1 Month Change | -5.80% |
3 Month Change | 0% |
1 Year Change | -63.89% |
3 Year Change | -83.40% |
5 Year Change | -96.26% |
Change since IPO | -99.60% |
Recent News & Updates
Recent updates
Shareholder Returns
NMLS.F | US Biotechs | US Market | |
---|---|---|---|
7D | 18.2% | -1.4% | -0.9% |
1Y | -63.9% | 7.2% | 25.8% |
Return vs Industry: NMLS.F underperformed the US Biotechs industry which returned 7.2% over the past year.
Return vs Market: NMLS.F underperformed the US Market which returned 25.8% over the past year.
Price Volatility
NMLS.F volatility | |
---|---|
NMLS.F Average Weekly Movement | 35.2% |
Biotechs Industry Average Movement | 11.3% |
Market Average Movement | 5.9% |
10% most volatile stocks in US Market | 16.0% |
10% least volatile stocks in US Market | 2.8% |
Stable Share Price: NMLS.F's share price has been volatile over the past 3 months.
Volatility Over Time: NMLS.F's weekly volatility has increased from 29% to 35% over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2004 | n/a | Will Rascan | www.novamentis.ca |
Nova Mentis Life Science Corp., through its subsidiaries, operates as a biotechnology company worldwide. It engages in developing diagnostics and psilocybin-based therapeutics for the treatment of neuroinflammatory disorders, including autism spectrum disorder and fragile X syndrome. The company was formerly known as Liberty Leaf Holdings Ltd.
Nova Mentis Life Science Corp. Fundamentals Summary
NMLS.F fundamental statistics | |
---|---|
Market cap | US$1.63m |
Earnings (TTM) | -US$895.90k |
Revenue (TTM) | n/a |
0.0x
P/S Ratio-1.8x
P/E RatioIs NMLS.F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
NMLS.F income statement (TTM) | |
---|---|
Revenue | CA$0 |
Cost of Revenue | CA$0 |
Gross Profit | CA$0 |
Other Expenses | CA$1.22m |
Earnings | -CA$1.22m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | -0.0083 |
Gross Margin | 0.00% |
Net Profit Margin | 0.00% |
Debt/Equity Ratio | 0% |
How did NMLS.F perform over the long term?
See historical performance and comparison